
Sparsentan treatment group experienced 49.8 percent mean reduction of proteinuria from baseline after 36 weeks, more than threefold the reduction of active comparator; interim primary efficacy endpoint achieved, p
On 6ix: 6ix.com/news/travere-therapeutics-announces-positive-topline-interim-results-from-the-ongoing

Sparsentan treatment group experienced 49.8 percent mean reduction of proteinuria from baseline after 36 weeks, more than threefold the reduction of active comparator; interim primary efficacy endpoint achieved, p
Travere Therapeutics, Inc. on 6ix
Follow Travere Therapeutics into a list and get an email when it puts out news.
Follow Travere Therapeutics